Consensus Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.91 ^USD	-2.05%		-1.29%	-36.12%

Mar. 25	Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	DJ
Mar. 25	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Evolution of the average Target Price on Esperion Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b186f2dee5bf7557494.coZEBFs2bRlsfRqivtKK_0EURnZm4TJTn_cjrngJ3zI.Odk8R2hULH5cM1X7_ZzcrC9SAgQMpH072p1QmD547kAw0h1UMnoIKzsPUw~8bb1d9e5226ecae10786c7f45e4486d7

Analyst Recommendations on Esperion Therapeutics, Inc.

Needham Adjusts Price Target on Esperion Therapeutics to $9 From $10, Maintains Buy Rating	23-08-02	MT
TD Cowen Cuts Esperion Therapeutics' Price Target to $8 From $10, Maintains Outperform Rating	23-08-01	MT
Northland Securities Upgrades Esperion Therapeutics to Market Perform From Underperform, Raises Price Target to $2 From $1	23-08-01	MT
BofA Securities Upgrades Esperion Therapeutics to Buy From Underperform, Adjusts Price Target to $4 From $1.25	23-06-15	MT
Needham Adjusts Esperion Therapeutics Price Target to $10 From $12, Maintains Buy Rating	23-05-09	MT
Morgan Stanley Trims Price Target on Esperion Therapeutics to $3 From $9, Maintains Equalweight Rating	23-03-20	MT
Northland Securities Downgrades Esperion Therapeutics to Underperform From Market Perform, Adjusts PT to $1 From $5	23-03-16	MT
Needham Adjusts Price Target on Esperion Therapeutics to $12 From $16, Maintains Buy Rating	23-03-16	MT
BofA Downgrades Esperion Therapeutics to Underperform From Neutral, Adjusts Price Target to $1.50 From $8	23-03-16	MT
Credit Suisse Upgrades Esperion Therapeutics to Neutral From Underperform, Sees Downside Risk As More Limited; Lifts PT to $7 From $6.50	23-03-07	MT
Needham Adjusts Esperion Therapeutics' Price Target to $16 From $12, Maintains Buy Rating	23-03-06	MT
JPMorgan Chase Adjusts Price Target on Esperion Therapeutics to $9 From $8, Maintains Neutral Rating	23-02-27	MT
BofA Securities Reinstates Esperion Therapeutics at Neutral With $8 Price Target	23-02-27	MT
Morgan Stanley Upgrades Esperion Therapeutics to Equal Weight From Underweight, $9 Price Target	23-02-03	MT
Morgan Stanley Adjusts Price Target on Esperion Therapeutics to $9 From $7, Keeps Underweight Rating	22-11-02	MT
Credit Suisse Downgrades Esperion Therapeutics to Underperform from Neutral Given Relative Risk/Reward for Shares, Trims PT to $6 from $7	22-08-03	MT
Morgan Stanley Raises Esperion Therapeutics' Price Target to $7 From $5, Maintains Underweight Rating	22-07-15	MT
JPMorgan Upgrades Esperion Therapeutics to Neutral From Underweight; Price Target is $6	22-05-05	MT
HC Wainwright Initiates Esperion Therapeutics at Buy With $22 Price Target	22-03-10	MT
Credit Suisse Lowers Esperion Therapeutics' PT to $6 from $8 After Adjusting Near-Term Ramp in Bempedoic Acid Franchise Sales within Model; Keeps Neutral Rating	22-01-14	MT
Needham Adjusts Esperion Therapeutics' Price Target to $12 from $20, Keeps Buy Rating	21-12-09	MT
Goldman Sachs Adjusts Esperion Therapeutics' Price Target to $5 from $8, Keeps Sell Rating	21-12-06	MT
Credit Suisse Lowers Esperion Therapeutics' PT to $8 from $11 on Heels of Dilutive Secondary Financing, Keeps Neutral Rating	21-12-06	MT
ESPERION THERAPEUTICS : Credit Suisse Downgrades Esperion Therapeutics to Neutral from Outperform on Restructuring News, Lowers PT to $11 from $28	21-10-19	MT
ESPERION THERAPEUTICS : Morgan Stanley Downgrades Esperion Therapeutics to Underweight Rating From Equal-Weight, Lowers PT to $11 From $17	21-10-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.91 USD

Average target price

7.414 USD

Spread / Average Target

+288.18%

High Price Target

16 USD

Spread / Highest target

+737.70%

Low Price Target

2.9 USD

Spread / Lowest Target

+51.83%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Esperion Therapeutics, Inc.

Needham & Co.
Northland Securities
TD Cowen
BofA Securities
Morgan Stanley
Credit Suisse
JPMorgan Chase
HC Wainwright
Goldman Sachs
JMP Securities
Stifel Nicolaus
BTIG
Jefferies & Co.

Ratings for Esperion Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar